title: It's a SMAD/SMAD World.
abstract: DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.
authors.affiliation: Departments of Radiation Oncology, Experimental Radiation Oncology, and Cancer Biology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: ctaniguchi@mdanderson.org.
authors.forename: Cullen
authors.initials: C
authors.lastname: Taniguchi
authors.affiliation: Departments of Pathology and Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA.
authors.forename: Anirban
authors.initials: A
authors.lastname: Maitra
mesh_terms: D000818:Animals; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism*; D050677:Core Binding Factor Alpha 3 Subunit / Q000378:metabolism*; D006801:Humans; D009362:Neoplasm Metastasis / Q000235:genetics*; D010190:Pancreatic Neoplasms / Q000378:metabolism*
chemical_list: D050677:Core Binding Factor Alpha 3 Subunit